HDL Nanoparticles Sequester LPS Endotoxins
Solution Overview
Problem
Current treatments for sepsis, particularly those targeting the aggressive immune response triggered by lipopolysaccharides (LPS), are inadequate, leading to high mortality rates and significant healthcare costs, as existing therapies focus on symptom management rather than directly addressing the inflammatory response caused by LPS.
Innovation Solution
Development of HDL nanoparticles (HDL-NPs) with specific physical-chemical properties, including a zeta potential of less than −30 mV, composed of a core surrounded by a lipid layer shell and apolipoprotein, which effectively bind endotoxins like LPS, reducing the severity of the immune response, even at sub-therapeutic doses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional sepsis treatments focusing on symptom management are used, then immediate symptomatic relief is achieved, but the aggressive immune response triggered by LPS is not effectively targeted, resulting in high mortality rates
Solution Approach 1:
The patent uses HDL nanoparticles as an intermediary substance that binds to LPS endotoxins, preventing them from triggering the aggressive immune response. The nanoparticles act as a mediator between the harmful LPS and the immune system, sequestering the endotoxins and reducing their pathogenic effects without directly interfering with the immune response mechanisms.
Solution Approach 2:
The invention converts the harmful LPS endotoxins into a beneficial state by having them bound and sequestered by the HDL nanoparticles. The LPS that would normally trigger a deadly immune response is transformed into a neutralized complex that can be safely cleared from the body, turning the harmful endotoxin into a harmless bound form.
2Object-affected harmful factors
If antibiotics are administered to eradicate bacterial infection, then bacterial growth is eliminated, but detached LPS remains capable of inducing severe immune response
Solution Approach 1:
The patent extracts and removes the harmful LPS endotoxins from the system by having them bound and sequestered by the HDL nanoparticles. This extraction process separates the LPS from its harmful free state, allowing it to be cleared from the body while antibiotics handle the bacterial eradication, addressing both harmful factors simultaneously.
Solution Approach 2:
The HDL nanoparticles serve as an intermediary that specifically targets and binds to LPS endotoxins, creating a separate pathway for LPS neutralization independent of antibiotic action. This intermediary mechanism allows simultaneous handling of both bacterial eradication and LPS neutralization without interference between the two therapeutic approaches.
3Reliability
If high doses of therapeutic agents are used to treat sepsis, then more aggressive immune response suppression is achieved, but treatment costs and potential side effects increase
Solution Approach 1:
The patent changes key parameters of the therapeutic approach by using nanoparticles with specific physical-chemical properties (zeta potential less than -30 mV, specific lipid composition including cardiolipin, PE, DPPC, and PG). These parameter changes enable the HDL nanoparticles to effectively bind LPS at sub-therapeutic doses, achieving immune response control without requiring high quantities of therapeutic substance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
HDL-NPs demonstrate the ability to stably bind LPS and significantly reduce LPS-induced immune responses, offering a novel approach to treating sepsis by mitigating the inflammatory cascade, potentially lowering mortality rates and treatment costs.
Implementation Method 1
the HDL-NP has a zeta potential of less than −30 mV
Data Source
AI summary
The invention in aspects relates to methods of treating sepsis using HDL-NP. The methods include the use of nanoparticles having a core and a lipid based shell with optimal lipids therein.